Brind.
  1. Compass Pathways established its operational footprint as of July 2025, including headquarters in London, offices in New York, and Breakthrough Therapy designation from the FDA.

RBC Capital Markets provides analyst commentary regarding the FDA's regulation of psychedelic drug development at Compass.

1 report, 0 independent Updated Jun 23
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

SpeculativeNo independent reporting found

RBC Capital Markets provides analyst commentary regarding the FDA's regulation of psychedelic drug development at Compass.

Who's involved

What this event is mainly about

Keep exploring

The entities involved

Coverage

Newest first; wire copies grouped
  • Unknown outlet